PAUL BROWN: Open Payments
NPI 1831284405 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$898 in 49 payments from 11 companies in 2025. Trend: 2023 $463 · 2024 $595 · 2025 $898
Food & beverage: $898
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $503 |
| Janssen Biotech, Inc. | 5 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| PFIZER INC. | 3 | $59 |
| Ardelyx, Inc. | 3 | $43 |
| GENZYME CORPORATION | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 2 | $18 |
Products named: LINZESS, SKYRIZI, RINVOQ, TREMFYA, ENTYVIO, VELSIPITY, IBSRELA, MAVYRET.
Industry payments across FL — which companies pay providers there.
